A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）

The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and <18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.

Start Date29 Dec 2025

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

NCT07135141

/ Not yet recruitingNot ApplicableIIT

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Superiority Trial

The SMART study is a 96-week, multicenter, randomized, double-blind, placebo-controlled superiority clinical trial. A total of 256 severe obesity patients are randomized 1:1 to either receive the bariatric surgery plus GCG/GLP-1 dual receptor agonist group (receiving sleeve gastrectomy followed by subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the bariatric surgery plus placebo group (receiving matched procedure plus placebo injections). The primary objective is to evaluate the potential enhancing weight reduction effects of the combination therapy with bariatric surgery and mazdutide measured by the percentage change of excess weight loss.

Start Date30 Sep 2025

Sponsor / Collaborator

Beijing Friendship Hospital

ChiCTR2600117503

/ RecruitingPhase 4IIT

Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes with Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial

Start Date27 Sep 2025

Sponsor / Collaborator

Nanjing Drum Tower Hospital

100 Clinical Results associated with Mazdutide

100 Translational Medicine associated with Mazdutide

100 Patents (Medical) associated with Mazdutide

Literatures (Medical) associated with Mazdutide

01 Feb 2026·Lancet Diabetes & Endocrinology

Obesity in China: current progress and future prospects

Review

Author: Fang, Zhong-Ze ; Zhang, Lingli ; Pan, Xiong-Fei ; Pan, An

The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenges in obesity across public health and policy, clinical research, and practice. National policy frameworks, technical health and nutrition guidelines, and multisectoral collaboration have elevated obesity on the public agenda. Evidence supporting lifestyle interventions and medications for obesity continues to accumulate. Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care. Nevertheless, several key challenges remain which can undermine the sustained impact of the progress. These include limitations in existing diagnostic criteria for obesity which captures phenotypic and cardiometabolic heterogeneity; limited availability of quantifiable, actionable, and accountable national targets which weakens governance and evaluation; and a scarcity of evidence-based algorithms for obesity pharmacotherapy, which risks over-reliance on medication and diverts attention from socioeconomic, environmental, and behavioural determinants. We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support.

01 Jan 2026·Contemporary Clinical Trials

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Article

Author: Li, Shu ; Zhou, Runze ; Li, Yunfeng ; Cai, Hanqing ; Luo, Yingying ; Qian, Lei ; Li, Li ; Ji, Linong ; Qiu, Wei ; Shi, Bimin ; Guo, Qun ; Pei, Lijuan ; Jiang, Hongwei ; Zhang, Han Han ; Wang, Haifang ; Deng, Huan

BACKGROUND:

Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential for enhanced weight loss compared to current standards of care. However, robust clinical evidence for these agents in populations with T2D and obesity is still lacking. The DREAMS-3 trial is designed to address this gap by directly comparing the efficacy and safety of mazdutide against semaglutide, a widely used GLP-1 receptor agonist, in Chinese adults with T2D and obesity. The results will provide crucial evidence to inform clinical decision-making for this large patient population.

METHODS:

DREAMS-3 is a randomized, open-label phase 3 trial. Obese Participants (BMI ≥ 28 kg/m²) diagnosed with T2D (≤ 10 years) who had inadequate glycemic control after diet and exercise alone with/without metformin were randomized in a 1:1 ratio to receive mazdutide 6 mg or semaglutide 1 mg once weekly in the 32-week active-controlled treatment period, followed with a 24-week extension period. The primary endpoint is the proportion of participants achieving glycated hemoglobin <7.0 % and weight reduction of ≥10 % at week 32.

RESULTS:

A total of 349 participants were enrolled and randomized, the overall mean age was 42.4 years, 44.7 % of participants were male. The mean baseline duration of T2D was 1.8 years, and 39.5 % of participants were on metformin. The mean glycated hemoglobin was 8.0 %, body weight was 90.5 kg, BMI was 33.0 kg/m². Most participants had at least one comorbidity. The prevalence of some comorbidities (such as metabolic associated fatty liver disease, gout/hyperuricemia) showed strong association of BMI.

CONCLUSION:

DERAMS-3 is the first head-to-head trial to compare the efficacy and safety of mazdutide versus semaglutide in Chinese adults with T2D and obesity, with an expected completion date in early 2026.

01 Jan 2026·PHARMACOLOGICAL RESEARCH

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

Review

Author: Hardaway, J Andrew ; Habegger, Kirk ; Elmendorf, Andrew J ; Flak, Jonathan N ; Kim, Il-Man ; Yousefian, Mostafa

The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation of treatment, the amount of which can depend on the treatment and patient, iterative advancements may improve weight loss durability in the long term. In this review, we discuss the development of glucagon like peptide-1 receptor (GLP-1R) agonists and GLP-1R/ glucose-dependent insulinotropic polypeptide receptor (GIPR) co-agonists, and how future generations will leverage this strategy. We focus our review on glucagon receptor (GCGR) agonism, which has recently been combined with both GLP-1R and GLP-1R/GIPR agonism to generate dual (e.g. survodutide, cotatutide, mazdutide, etc) and triple agonists (e.g. retatrutide, etc) for improved body weight loss via energy expenditure stimulation. We rely on largely pre-clinical evidence for action because clinical data is extremely limited for GCGR agonism. Herein, we review mechanisms by which glucagon receptor agonists act to increase energy expenditure. Finally, we discuss future improvements to incretin-based therapeutics, and how they can include strategies that target the GCGR. The purpose of this review is to discuss mechanisms by which GCGR agonism can reduce body weight and put them in the context of the combination with incretin receptor agonists. Mechanistic data has only currently been evaluated in preclinical rodent models and evidence for similar processes in humans is limited. We also provide perspectives about how treatments can improve for future advancement of obesity treatment.

News (Medical) associated with Mazdutide

26 Feb 2026

·www.opko.com

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront payment and is entitled to potential milestone payments exceeding $200 million for each program. The overall potential value of the collaboration exceeds $1 billion if multiple products from the collaboration are successful. In addition, ModeX is eligible to receive tiered royalties on global net sales, reaching low double digits at the highest tier. Regeneron is responsible for funding all preclinical and clinical development, as well as all commercialization activities. Merck completed the Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck. The Phase 1 trial evaluating safety and tolerability in over 200 healthy adults was completed in the fourth quarter of 2025. Additional studies are in progress to inform dose and adjuvant selection for potential Phase 2 studies. MDX2003, a first-in-class trispecific T-cell engager-expander for the treatment of leukemia and lymphoma, was approved for Phase 1 studies in Australia, which are expected to begin in the first half of 2026. Also, an abstract was presented at 2025 ASH Annual Meeting. In November, an abstract titled “MDX2003, a novel tetraspecific T cell engager-expander targeting CD19xCD20xCD3xCD28, demonstrates potent preclinical activity against B cell malignancies” was presented at the American Society of Hematology’s 67th ASH Annual Meeting and Exposition. In an animal model, MDX2003 prevented further tumor growth at low doses and was well-tolerated with low levels of cytokines in the blood and no observable toxicity. Abstract for MDX2004, a first-in-class trispecific antibody-fusion protein immune rejuvenator, was presented at SITC 2025. In November, an abstract titled “MDX2004, a novel immune rejuvenator targeting CD3, CD28, and 4–1BB, augments tumor immunity in preclinical animal models” was presented at SITC 2025, the annual meeting of the Society for Immunotherapy of Cancer. The ongoing Phase 1/2a study (NCT07110584) is designed to evaluate the safety, tolerability and biologic activity of MDX2004 as an immunotherapy for advanced cancers. Abstract for MDX2001 cMet-Trop2/CD3-CD28, a first-in-class tetraspecific T-cell engager, was presented at ESMO 2025. In October, an abstract titled “A phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors” was presented at ESMO Congress 2025, the annual meeting of the European Society for Medical Oncology. The MDX2001 cMet-Trop2/CD3-CD28 tetraspecific antibody has advanced to the fifth dose level in its Phase 1 clinical trial, with Phase 1b studies in select solid tumors expected to begin in the first half of 2026. FDA permission to proceed to Phase 1 granted to MDX2301, a tetravalent bispecific antibody that neutralizes all known strains of SARS-CoV2, for the prevention and treatment of COVID-19 infection. Supported by non-dilutive funding from BARDA, the clinical trial in healthy volunteers is scheduled to begin in the second quarter of 2026, with pharmacokinetic and immunogenicity data expected later this year. Expanded partnership with Entera Bio to advance first-in-class oral long-acting PTH tablet for patients with hypoparathyroidism. This third program under the collaboration combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab® technology. Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2026. OPKO and Entera Bio each hold a 50% pro-rata ownership interest in the long-acting PTH hypoparathyroidism program and each is responsible for 50% of the program's development costs. Fourth Quarter Financial Results Consolidated: Consolidated total revenues for the fourth quarter of 2025 were $148.5 million compared with $183.6 million for the 2024 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the fourth quarter of 2025 was $38.3 million compared with operating loss of $33.1 million for the 2024 quarter. Net loss for the fourth quarter of 2025 was $31.3 million, or $0.04 per share, compared with net income of $14.0 million, or $0.01 per diluted share, for the 2024 quarter. Net income for the fourth quarter of 2024 included a realized gain of $54.1 million from the sale of shares of GeneDx, as well as non-cash other income of $21.4 million. Pharmaceuticals: Revenue from products in the fourth quarter of 2025 was $43.7 million compared with $37.4 million in the fourth quarter of 2024, driven by a positive net foreign exchange impact of $4.0 million and by higher sales volumes in our international operations. Revenue from Rayaldee was $8.8 million compared with $9.1 million in the comparable prior-year quarter. Revenue from the transfer of intellectual property and other was $33.7 million in the fourth quarter of 2025 compared with $43.1 million in the 2024 period. Gross profit share payments for NGENLA, which totaled $12.5 million in the 2025 period compared with $9.6 million in the 2024 period, reflect the global commercial progress by Pfizer. In addition, the fourth quarter of 2025 included $4.3 million in royalty revenue from Eli Lilly following the commercial launch of mazdutide in China by their partner Innovent Biologics and a $7.0 million upfront payment from Regeneron. The comparable period of 2024 included a $12.5 million milestone payment from Merck, as well as a $7.0 million decrease in commercial milestones at our Eirgen business and a $4.1 million decrease in revenue from our contract with BARDA. Total costs and expenses increased to $88.0 million in the fourth quarter of 2025 from $82.6 million in the prior-year period, primarily due to higher cost of revenue related to higher sales volume, higher research and development expenses driven by advancements in early-stage programs and employee-related expenses reflecting an increase in headcount to support ongoing clinical activities. Operating loss was $10.7 million in the fourth quarter of 2025, which included $18.3 million in depreciation and amortization expense, compared with operating loss of $2.1 million in the fourth quarter of 2024, which included $18.1 million of depreciation and amortization expense. Diagnostics: Revenue from services in the fourth quarter of 2025 was $71.1 million compared with $103.1 million in the prior-year period. The decrease was principally a result of the sale of certain BioReference assets in 2025 and the resulting decline in clinical test volume, and lower clinical test reimbursement rates, partially offset by increased demand and higher average reimbursement for the 4Kscore test, resulting in a 16% increase in revenue to $7.0 million in the 2025 quarter compared with $6.0 million in revenue in the 2024 quarter. Total costs and expenses were $89.4 million in the fourth quarter of 2025 compared with $124.8 million in the fourth quarter of 2024. The decrease was primarily attributable to the assets sold and to continued cost-reduction initiatives at BioReference. Operating loss was $18.3 million in the fourth quarter of 2025, which included $4.1 million of depreciation and amortization expense, compared with operating loss of $21.7 million in the 2024 period, which included $6.0 million of depreciation and amortization expense. The fourth quarter of 2025 was impacted by non-recurring transition-related adjustments of $5.8 million, primarily from severance, asset write-offs, third-party revenue adjustments, and capital tax expense. The fourth quarter of 2024 included revenue of $26.3 million and costs and expenses of $32.9 million from the oncology assets that were sold to Labcorp on September 15, 2025. Cash, cash equivalents, marketable securities and restricted cash: Cash, cash equivalents and restricted cash were $369.1 million as of December 31, 2025. As of December 31, 2025, approximately $87.3 million of OPKO’s common stock had been repurchased, including $13.5 million in the fourth quarter of 2025, under the program since its authorization in July 2024. Approximately $112.7 million remained authorized and available for future repurchases. 2026 Financial Guidance: The table below reflects financial guidance for the first quarter and full year 2026 (in millions): Conference Call and Webcast Information OPKO’s senior management will provide a business update, discuss fourth quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call here. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here. A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2367034. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, visit www.opko.com. Cautionary Statement Regarding Forward Looking Statements This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether the collaboration with Regeneron will be successful and whether we will receive milestone payments and/or royalties as a result of that collaboration, whether the remaining BioReference business will become profitable, whether we will be able to submit Investigational New Drug applications for the oral and subcutaneous forms of GLP-1/glucagon and GLP-2 tablet and the timing of those submissions, whether we will have a successful collaboration with Entera, whether our product development efforts will be successful and whether the expected benefits of our products will be realized, including whether the data for MDX2004 will be positive, whether preclinical data will be indicative of clinical data should any of our preclinical programs progress into clinical development, whether the trial for MDX2001 and EBV will continue to progress and whether the data will be positive for all trials, including the EBV Vaccine trial, whether we will receive additional funding from BARDA, whether the relationship with our commercial and strategic partners will be successful, whether our commercial and strategic partners will be able to commercialize our products and successfully utilize our technologies, whether our partner will be able to continue to successfully commercialize NGENLA and the NGENLA profits will provide adequate upside, whether we will continue to repurchase shares under a buyback program, our ability to market and sell any of our products in development, whether we will continue to successfully advance products in our pipeline and whether they can be commercialized, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. Contacts: Alliance Advisors IR Yvonne Briggs, 310-691-7100 ybriggs@allianceadvisors.com or Bruce Voss, 310-691-7100 bvoss@allianceadvisors.com —Tables to Follow— Released February 26, 2026

VaccineImmunotherapyPhase 1Financial Statement

24 Feb 2026

·endpoints.news

Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push

Pfizer has recently gone shopping for investigational GLP-1 drugs in China to take them to the rest of the world. Now, the large drugmaker is going to China and staying there. The New York pharma giant is paying up to $495 million to get the China commercialization rights to an approved GLP-1 injectable from Sciwind Biosciences, the Hangzhou-based drug developer said on Tuesday. The companies didn’t disclose the split between upfront, regulatory and milestone payments. Pfizer will be competing with Novo Nordisk, Eli Lilly and Innovent in the Chinese market. The move comes a month after China’s drug regulator approved Sciwind’s GLP-1 receptor agonist, known as ecnoglutide, for adults with type 2 diabetes. The regulator is also reviewing the medicine for obesity. Ecnoglutide is also in clinical testing for a broad set of indications, including MASH, obstructive sleep apnea and other comorbidities. Pfizer has made obesity one of the core fixtures of its pipeline, alongside cancer, for the next decade. Attempting to move beyond its Covid-19 vaccine days, Pfizer duked it out with Wegovy maker Novo Nordisk last year in a bidding war for obesity biotech Metsera. It’s on the hook for up to $10 billion to Metsera shareholders and has outlined plans to start 10 Phase 3 trials this year for PF-08653944, the long-acting GLP-1 injectable from that deal. Weeks after buying Metsera, Pfizer supplemented that deal with a $150 million upfront pact for an oral GLP-1 medicine from China-based YaoPharma , a Fosun subsidiary. With Sciwind, Pfizer is getting immediate access to an approved medicine that it can sell in China, where about 148 million people have diabetes, according to the International Diabetes Federation. Ecnoglutide is one of a handful of approved GLP-1 medicines in China, joining Novo Nordisk’s semaglutide, Lilly’s tirzepatide and Innovent’s mazdutide. Sciwind will continue leading R&D, registration, manufacturing and supply of the drug in China, it said. In 2024, China’s government launched a three-year weight management campaign to address the rising rates of obesity in the world’s second most populous country. Pfizer’s China president Jean-Christophe Pointeau said in a statement that 14.1% of Chinese adults have obesity. The Sciwind deal, he said, “represents an important milestone in accelerating Pfizer’s long-term strategic expansion in the metabolic field.” Sciwind CEO Pan Hai told Reuters last July that Sciwind was in talks with an unnamed US company interested in ecnoglutide for American patients. It’s unclear whether he was referring to Pfizer, since Pfizer did not pick up the US rights to the drug. Sciwind filed for an IPO on the Hong Kong Stock Exchange a few months after that Reuters report to help bankroll its sprawling pipeline. Western biotech Verdiva Bio has rights to a once-weekly oral version of ecnoglutide, along with oral and injectable amylin candidates from Sciwind.

Drug ApprovalAcquisitionVaccineIPO

09 Feb 2026

·www.fiercebiotech.com

Lilly, Innovent pen $8.8B oncology, immunology collab that \'moves beyond traditional licensing\'

Eli Lilly and Innovent have penned six previous agreements together.\n Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders.The companies didn’t disclose the specific targets they have in mind nor how many drugs they expect to eventually be produced under their latest agreement, but, along with the upfront money, Suzhou, China-based Innovent is also in line for heavily backloaded development, regulatory and commercial milestone payments that could reach a combined total of $8.5 billion. Should these drugs make it to market, Innovent will be in line for royalties on sales outside of China.The plan is for Innovent to use its antibody platform to bring oncology and immunology programs from the drawing board through to the completion of a phase 2 study. From there, Lilly will take the drugs forward and secure the license for the assets outside greater China.Innovent said this “unique” deal structure “establishes a new model for Innovent to accelerate the global development of its innovative pipeline.”“This alliance moves beyond traditional licensing to create a seamless, end-to-end innovation ecosystem that combines our agile discovery and early-stage development engine with Lilly\'s extensive global scale and creates a highly efficient model for cross-border synergy,” Innovent CEO Michael Yu, Ph.D., said in a Feb. 8 release.“This partnership validates Innovent\'s R&D capabilities and allows us to accelerate the translation of scientific discoveries into impactful global medical solutions together with our partner, with the ultimate goal of bringing world-class medicines to patients across the globe,” Yu added. Lilly and Innovent are old friends, having penned six previous agreements together. Those collaborations have included Innovent bagging the rights to the U.S. pharma’s next-gen obesity drug mazdutide in China, where it scored regulatory approval last year.Not all of the companies’ link-ups have been as successful. In 2022, Lilly dumped Innovent’s PD-1 inhibitor Tyvyt—once billed as a potential low-cost choice in a multibillion-dollar class—after the FDA turned down an approval for non-small cell lung cancer and castigated the partners for using China-only pivotal data that compared the experimental therapy to an outdated regimen.For the final quarter of 2025, Lilly’s R&D spend rose 26% year over year to $3.8 billion, or 20% of revenue, according to the company’s earnings report last week.

License out/inDrug Approval

100 Deals associated with Mazdutide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	China	Innovent Biologics (Suzhou) Co. Ltd.	16 Sep 2025
Obesity	China	Innovent Biologics (Suzhou) Co. Ltd.	24 Jun 2025
Overweight	China	Innovent Biologics (Suzhou) Co. Ltd.	24 Jun 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	28 Feb 2026
Sleep Apnea, Obstructive	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	13 May 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	22 Apr 2025
Early-onset type II diabetes	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	29 Feb 2024
Metabolic Dysfunction Associated Steatohepatitis	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	20 Jun 2025
Heart failure with mid range ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Heart failure with normal ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Heart failure with reduced ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Hyperuricemia	Preclinical	China	Innovent Biologics (Suzhou) Co. Ltd.	12 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05628311 (DREAMS-1, Nature \| Pubmed \| PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	320	Mazdutide 4 mg	jkqbjbzzrg(yvghxrhzzs) = wydqkwrysz mtylachfwk (mkcalxvmsz ) Met View more	Positive	17 Dec 2025
				Mazdutide 6 mg	jkqbjbzzrg(yvghxrhzzs) = vhydyhvigk mtylachfwk (mkcalxvmsz ) Met View more
NCT05606913 (DREAMS-2, Nature \| Pubmed \| PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	731	Mazdutide 4 mg	hwglxbfaud(bzzaogrjin) = axizlpvbcn bqzxwiaatv (hbdsavhmpu ) Met View more	Superior	17 Dec 2025
				Mazdutide 6 mg	hwglxbfaud(bzzaogrjin) = nmwhqcnllb bqzxwiaatv (hbdsavhmpu ) Met View more
PRNewswire Manual	Phase 1	Obesity	36	mazdutide 4 mg	erltwagvyi(ezbauhkjta) = jncduiddyn nqkldcwsgu (wqrmcjkbhd ) Met View more	Positive	11 Dec 2025
				mazdutide 6 mg	erltwagvyi(ezbauhkjta) = jricjruzqe nqkldcwsgu (wqrmcjkbhd ) Met View more
NCT06164873 (GLORY-2, Company_Website) Manual	Phase 3	Obesity	462	Mazdutide 9 mg	tkvxvtmmuc(cetxllqtrw) = fckolimmzl ecbdabkglp (hukmtahcbh ) Met View more	Positive	20 Nov 2025
				Placebo	tkvxvtmmuc(cetxllqtrw) = qpkvehuvhp ecbdabkglp (hukmtahcbh ) Met View more
NCT05623839 (Pubmed \| Diabetes Obes Metab)	Phase 1	Overweight \| Obesity	32	Mazdutide (Cohort 1)	drayfssrrb(bqnyergoey) = the most common AEs were mild or moderate gastrointestinal disorders. gsbgljlgpv (xvfyqoxltz )	Positive	01 Nov 2025
				Mazdutide (Cohort 2)
NCT06184568 (DREAMS-3, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	349	mazdutide 6 mg	bxmxaibzrm(slgkehxqav) = seljfaqber vtyyskljya (kosxvytmvg ) Met View more	Positive	26 Oct 2025
				semaglutide 1 mg	bxmxaibzrm(slgkehxqav) = uzawuytpem vtyyskljya (kosxvytmvg ) Met View more
NCT05607680 (GLORY-1, Pubmed) Manual	Phase 3	Overweight \| Obesity	610	mazdutide 4mg	trobxyohoc(sfdceopfdw) = nllheylhji eitqeyvlgw (wipvrekvoi, -11.15 to -9.04) View more	Positive	24 May 2025
				mazdutide 6mg	trobxyohoc(sfdceopfdw) = zamnsgudwq eitqeyvlgw (wipvrekvoi, -13.64 to -11.45) View more
NCT05607680 (GLORY-1, NEWS) Manual	Phase 3	Overweight \| Obesity	610	Mazdutide	jijdmvkfqb(gpjnqnderx) = dqskhkkfak lkznvpixxc (knlskenrry ) View more	Positive	13 Sep 2024
				Mazdutide (4 mg)	rqogtwdjgg(jfwfkrmzar) = ztfgdaklil jwzxjzaaih (hrwtxpmrob ) View more
NCT05606913 (DREAMS-2, EASD2024) Manual	Phase 3	Diabetes Mellitus, Type 2	731	mazdutide 4mg	hfixbbdekq(scsbofsecj) = cmpdgcjxwo pxyxhsnwdy (cvrfelaccr ) View more	Positive	11 Sep 2024
				mazdutide 6mg	hfixbbdekq(scsbofsecj) = svhqfclfqz pxyxhsnwdy (cvrfelaccr ) View more
NCT05623839 (EASD2024) Manual	Phase 1	Overweight \| Obesity	32	Mazdutide (cohort 1)	gcpdufkfyf(zfhfhvteyx) = xbuakqkfwo hgbqeoomuk (ydzhelongd ) View more	Positive	09 Sep 2024
				Mazdutide (cohort 2)	gcpdufkfyf(zfhfhvteyx) = sigjdygiqs hgbqeoomuk (ydzhelongd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis